Literature DB >> 10495427

zo-2 gene alternative promoters in normal and neoplastic human pancreatic duct cells.

A Chlenski1, K V Ketels, J L Engeriser, M S Talamonti, M S Tsao, H Koutnikova, R Oyasu, D G Scarpelli.   

Abstract

We have observed that 2 forms of zonula occludens 2 (ZO-2) protein, ZO-2A and ZO-2C, are expressed in normal human pancreatic duct cells, but only ZO-2C in pancreatic duct adenocarcinoma. We report here partial organization of the zo-2 gene. Transcription of 2 forms of ZO-2 mRNA is driven by alternative promoters P(A) and P(C). Lack of expression of ZO-2A in neoplastic cells is caused by inactivation of the downstream promoter P(A). Analysis of the promoter P(A) sequence and function in normal and neoplastic cells demonstrated that neither structural changes (mutations) nor a change in the pool of transcription factors is responsible for its inactivation. Although hypermethylation was found in a large number of cancer clones, treatment with 5-aza-2'-deoxycytidine did not fully cause the promoter function to recover. We conclude that the initial down-regulation of zo-2 promoter P(A) activity in pancreatic duct carcinomas is due to the structural or functional alteration(s) in the regulatory elements, localized outside the analyzed promoter region. Methylation of P(A) is responsible for the inactivation of the suppressed promoter at the late stages of tumor development. Copyright 1999 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10495427     DOI: 10.1002/(sici)1097-0215(19991029)83:3<349::aid-ijc10>3.0.co;2-c

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  6 in total

1.  Link of the unique oncogenic properties of adenovirus type 9 E4-ORF1 to a select interaction with the candidate tumor suppressor protein ZO-2.

Authors:  B A Glaunsinger; R S Weiss; S S Lee; R Javier
Journal:  EMBO J       Date:  2001-10-15       Impact factor: 11.598

2.  ZO-2 favors Hippo signaling, and its re-expression in the steatotic liver by AMPK restores junctional sealing.

Authors:  Laura González-González; Helios Gallego-Gutiérrez; Dolores Martin-Tapia; José Everardo Avelino-Cruz; Christian Hernández-Guzmán; Sergio Israel Rangel-Guerrero; Luis Marat Alvarez-Salas; Erika Garay; Bibiana Chávez-Munguía; María Concepción Gutiérrez-Ruiz; Dinorah Hernández-Melchor; Esther López-Bayghen; Lorenza González-Mariscal
Journal:  Tissue Barriers       Date:  2021-10-23

3.  Cyclin D1 is transcriptionally down-regulated by ZO-2 via an E box and the transcription factor c-Myc.

Authors:  Miriam Huerta; Rodrigo Muñoz; Rocío Tapia; Ernesto Soto-Reyes; Leticia Ramírez; Félix Recillas-Targa; Lorenza González-Mariscal; Esther López-Bayghen
Journal:  Mol Biol Cell       Date:  2007-09-19       Impact factor: 4.138

4.  Oncogenic function for the Dlg1 mammalian homolog of the Drosophila discs-large tumor suppressor.

Authors:  Kristopher K Frese; Isabel J Latorre; Sang-Hyuk Chung; Georgina Caruana; Alan Bernstein; Stephen N Jones; Lawrence A Donehower; Monica J Justice; Craig C Garner; Ronald T Javier
Journal:  EMBO J       Date:  2006-03-02       Impact factor: 11.598

5.  Androgen-dependent sertoli cell tight junction remodeling is mediated by multiple tight junction components.

Authors:  Papia Chakraborty; F William Buaas; Manju Sharma; Benjamin E Smith; Anne R Greenlee; Stephen M Eacker; Robert E Braun
Journal:  Mol Endocrinol       Date:  2014-05-13

Review 6.  Cell polarity proteins: common targets for tumorigenic human viruses.

Authors:  R T Javier
Journal:  Oncogene       Date:  2008-11-24       Impact factor: 9.867

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.